Clinical trials: High-dose Chemotherapy
Hypertension
Efficacy/Safety Study of Valsartan and Chlorthalidone Conjugate Treatment Compared to Simple Treatment for Hypertension
This trial is aimed to assess the efficacy and safety of a fixed-dose combination therapy with Valsartan and Chlorthalidone, Vs Valsartan or Chlorthalidone alone for treatment of adult patients with diagnosis of arterial…
- Trial name
- NCT01850160
- Testing
- GROUP A: Valsartan plus Chlorthalidone, GROUP B: Valsartan, GROUP C: Chlorthalidone
- Where
- 8 sites in Colombia, Ecuador
- Volunteers
- 124 people
- Sponsor
- Farma de Colombia SA
Lymphoma, Non-Hodgkin
A Study Of Inotuzumab Ozogamicin Plus Rituximab For Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma Patients Who Are Not Candidates For Intensive High-Dose Chemotherapy
The purpose of this study is to evaluate the efficacy of inotuzumab ozogamicin plus rituximab in relapsed/refractory aggressive Non-Hodgkin lymphoma patients who are not candidates for intensive high-dose chemotherapy.
- Trial name
- NCT01232556
- Testing
- Inotuzumab ozogamicin, Rituximab, rituximab + gemcitabine
- Where
- 177 sites in United States, Belgium and 23 more
- Volunteers
- 338 people
- Sponsor
- Pfizer
Nausea and Vomiting Chemotherapy-Induced, Nausea Post Chemotherapy
Study With IV NEPA (Fosnetupitant/Palonosetron) for the Prevention of Chemotherapy-induced Nausea and Vomiting in Paediatric Cancer Patients Undergoing Highly Emetogenic Chemotherapy (HEC)
Chemotherapy often causes nausea and vomiting (CINV), and this is a major problem for the children being treated for cancer. To prevent this, a combination of two substances in fixed proportion (IV NEPA) was developed.
- Trial name
- NCT06904235
- Testing
- IV NEPA (fosnetupitant/palonosetron), Reference Treatment: IV ondansetron infusion, Reference Treatment: IV fosaprepitant infusion
- Where
- 20 sites in Greece, Poland and 2 more
- Volunteers
- 95 people
- Sponsor
- Helsinn Healthcare SA
Oral Mucositis
Gelclair at Conditioning or After Oral Mucositis Diagnosed vs. Magic Mouth Wash in Stem Cell Transplant Recipients
Patients receiving high-dose chemotherapy/conditioning prior to stem cell transplantation (SCT) are at high risk for developing painful lesions in the oral cavity, known as oral mucositis (OM).
- Trial name
- NCT03490396
- Testing
- Gelclair, First® Mouthwash BLM
- Where
- 2 sites in United States
- Volunteers
- 28 people
- Sponsor
- Midatech Pharma US Inc.
Non-Hodgkin Lymphoma, Hodgkin Disease
Safety and Efficacy of (PN-152,243)/PN-196,444 in the Prevention of Thrombocytopenia
Intensive chemotherapy is associated with significant thrombocytopenia, often requiring platelet transfusion to maintain platelet counts. This investigational drug has been demonstrated to increase platelet counts.
- Conditions
- Non-Hodgkin Lymphoma, Hodgkin Disease, Thrombocytopenia
- Trial name
- NCT00039910
- Testing
- (PN-152,243)/ PN-196,444
- Where
- 38 sites in United States, Australia and 6 more
- Volunteers
- 240 people
- Sponsor
- Pfizer
Chemotherapy-induced Nausea and Vomiting (CINV)
Aprepitant/MK0869 for Prevention of Chemotherapy Induced Nausea and Vomiting Associated With Cisplatin (0869-169)(COMPLETED)
This study will demonstrate and confirm the efficacy and safety of MK0869 for the treatment of chemotherapy-induced nausea and vomiting in Chinese patients.
- Trial name
- NCT00952341
- Testing
- aprepitant, dexamethasone, granisetron
- Volunteers
- 421 people
- Sponsor
- Merck Sharp & Dohme LLC
Multiple Sclerosis
High Dose Chemo With Stem Cell Transplant as Treatment for Multiple Sclerosis That Failed Prior Treatment
The purpose of this study is to evaluate the toxicity and the effectiveness of high dose chemotherapy with HPC transplant Multiple Sclerosis that has failed at least two lines of therapy
- Trial name
- NCT01679041
- Testing
- Alemtuzumab, Fludarabine, Cyclophosphamide
- Where
- 3 sites in United States
- Volunteers
- 1 people
- Sponsor
- Seah Lim M.D.
Chemotherapy-Induced Nausea and Vomiting
Phase 2 Study of Efficacy, Tolerability, and Safety of Intranasal Granisetron for Chemo-Induced Nausea and Vomiting
Brief Summary: A randomized, single administration, double-blind, parallel- group Phase 2 dose finding study to assess the efficacy, tolerability, and safety of TRG in patients with chemotherapy-induced nausea and vomiting (CINV)…
- Trial name
- NCT00787566
- Testing
- Intranasal granisetron
- Where
- United States
- Volunteers
- 68 people
- Sponsor
- Shin Nippon Biomedical Laboratories, Ltd.
Multiple Myeloma (MM)
A Study of Linvo-VR vs DVRd in Transplant-Eligible Adult Participants With Newly Diagnosed Multiple Myeloma (NDMM)
This study is focused on participants with Newly Diagnosed Multiple Myeloma (NDMM) who are eligible for high dose chemotherapy followed by Autologous Stem Cell Transplantation (ASCT).
- Trial name
- LINKER-MM8 (NCT07428369)
- Testing
- Linvoseltamab, Bortezomib, Lenalidomide
- Sponsor
- Regeneron Pharmaceuticals
Hyperlipidemia
Monoclonal Antibody Against PCSK9 to Reduce Elevated Low-density Lipoprotein Cholesterol (LDL-C) in Adults Currently Not Receiving Drug Therapy for Easing Lipid Levels
The primary objective was to evaluate the effect of 12 weeks of subcutaneous evolocumab (AMG 145) every 2 weeks (Q2W) or every 4 weeks (Q4W), compared with placebo, on the percent change from baseline in LDL-C when used as…
- Trial name
- MENDEL (NCT01375777)
- Testing
- Evolocumab, Ezetimibe
- Where
- 58 sites in United States, Australia and 3 more
- Volunteers
- 411 people
- Sponsor
- Amgen
Acute Myeloid Leukemia
Ex-vivo Expanded γδ T-lymphocytes (OmnImmune®) in Patients With Acute Myeloid Leukaemia (AML)
This study investigates the potential curative properties of gamma delta T-cells obtained from a blood-related donor of an AML patient.
- Trial name
- NCT03790072
- Testing
- OmnImmune®
- Where
- Czechia
- Volunteers
- 10 people
- Sponsor
- TC Biopharm
Multiple Myeloma
Study Comparing Daratumumab, Lenalidomide, Bortezomib, and Dexamethasone (D-RVd) Versus Lenalidomide, Bortezomib, and Dexamethasone (RVd) in Subjects With Newly Diagnosed Multiple Myeloma
The purpose of this study is to determine if the addition of daratumumab to lenalidomide-bortezomib-dexamethasone (RVd) will increase the proportion of participants achieving stringent complete response (sCR), as defined by the…
- Trial name
- NCT02874742
- Testing
- Lenalidomide, Bortezomib, Dexamethasone
- Where
- 36 sites in United States
- Volunteers
- 224 people
- Sponsor
- Janssen Research & Development, LLC
Cachexia
A Dose Escalation Study of AV-380 in Cancer Patients With Cachexia
This open label ascending dose study is designed to evaluate the safety, pharmacokinetics (PK), pharmacodynamics (PD), and immunogenicity of AV-380 in cancer patients with Cachexia.
- Trial name
- NCT05865535
- Testing
- AV-380
- Where
- 12 sites in United States
- Volunteers
- 30 people
- Sponsor
- AVEO Pharmaceuticals, Inc.
Chemotherapy-Induced Nausea and Vomiting
An Efficacy and Safety Study of Intravenous Palonosetron Administered as an Infusion and as a Bolus for the Prevention of Nausea and Vomiting
PALO-15-17 is a clinical study assessing efficacy and safety of a single dose of palonosetron 0.25 mg administered as a 30-minute IV infusion compared to palonosetron 0.25 mg administered as a 30-second IV bolus (Aloxi, an…
- Trial name
- NCT02557035
- Testing
- Palonosetron, Dexamethasone
- Where
- 76 sites in Belarus, Bosnia and Herzegovina and 7 more
- Volunteers
- 441 people
- Sponsor
- Helsinn Healthcare SA
Acute Myeloid Leukemia
A Study Of PF-04449913 In Japanese Patients With Select Hematologic Malignancies
This is an open-label, multi-center, Phase 1 study of PF-04449913 in Japanese patients. PF-04449913 will be administered orally as a single agent in patients with select advanced hematologic malignancies, or in combination with…
- Trial name
- NCT02038777
- Testing
- PF-04449913, Low dose ARA-C (LDAC), Daunorubicin
- Where
- 9 sites in Japan
- Volunteers
- 48 people
- Sponsor
- Pfizer
Anemia
A Study of Recombinant Human Erythropoietin Beta (NeoRecormon) in Anemic Cancer Participants Treated With Chemotherapy
This study will evaluate the efficacy and tolerability of subcutaneous (SC) or intramuscular (IM) recombinant human erythropoietin beta (r-HuEPO) in participants with anemia and histologically or cytologically confirmed cancer.
- Trial name
- NCT02767765
- Testing
- r-HuEPO
- Where
- 7 sites in Italy
- Volunteers
- 61 people
- Sponsor
- Hoffmann-La Roche
Leukemia, Myelocytic, Acute
Comparison of Two Treatments in Intermediate and High-risk Acute Promyelocytic Leukemia (APL) Patients to Assess Efficacy in 1st Hematological Complete Remission and Molecular Remission
The study will compare the efficacy of the 2 treatments in intermediate and high-risk APL patients in achieving first hematological complete remission and molecular remission.
- Trial name
- NCT00962767
- Testing
- gemtuzumab ozogamicin, ATRA plus 6-MP and MTX
- Volunteers
- 168 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Neoplasm Metastasis
A Study of Olaratumab Alone and in Combination With Standard Chemotherapies in Children With Cancer
The main purpose of this study is to evaluate the safety of different doses of olaratumab and to determine which dose should be used for future pediatric studies.
- Trial name
- NCT02677116
- Testing
- Olaratumab, Doxorubicin, Vincristine
- Where
- 21 sites in United States, Japan
- Volunteers
- 68 people
- Sponsor
- Eli Lilly and Company
Leukemia, Myeloid, Acute
NLA101 in Adults Receiving High Dose Chemotherapy for AML
Phase 2 open-label, multi-center, randomized, controlled, dose-finding study of safety and efficacy of NLA101 to reduce the rate of infections associated with CIN in adult subjects with AML.
- Trial name
- LAUNCH (NCT03301597)
- Testing
- NLA101, Standard of Care (SOC) chemotherapy
- Where
- 36 sites in United States, Australia and 1 more
- Volunteers
- 146 people
- Sponsor
- Nohla Therapeutics, Inc.
Nausea, Vomiting
Aprepitant for the Prevention of Chemotherapy Induced Nausea and Vomiting (CINV) Associated With Highly Emetogenic Chemotherapy (0869-801)(COMPLETED)
A multicenter trial to assess the safety and efficacy of an investigational drug in the prevention of chemotherapy-induced nausea and vomiting (CINV) in patients with confirmed solid tumors who will be treated with a chemotherapy…
- Trial name
- NCT00090207
- Testing
- MK0869, aprepitant / Duration of Treatment: 3 days, Comparator: ondansetron / Duration of Treatment: 4 days
- Volunteers
- 477 people
- Sponsor
- Merck Sharp & Dohme LLC